Timing of nerve block may ease pain after chest surgery
NCT ID NCT07532681
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether giving a nerve block before or after video-assisted chest surgery (VATS) reduces pain better. 140 adults having VATS will receive two injections: one with a numbing drug (ropivacaine) and one with a placebo (saline). The timing of the active drug is swapped between groups. Researchers will measure pain scores and opioid use for 48 hours after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ropivacaine 0.375%
What this could lead to
If successful, this could help doctors choose the best timing for nerve blocks to reduce pain and opioid use after chest surgery.
What could go wrong
This is a small, early-stage study (140 people) comparing two timings of a standard procedure. The difference may be small or not clinically meaningful.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIDEO ASSISTED THORACIC SURGERY (VATS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HUB Erasme
Brussels, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••